Literature DB >> 16178749

Dihydro-beta-agarofuran sesquiterpenes: a new class of reversal agents of the multidrug resistance phenotype mediated by P-glycoprotein in the protozoan parasite Leishmania.

F Cortés-Selva1, I A Jiménez, F Munoz-Martínez, M Campillo, I L Bazzocchi, L Pardo, A G Ravelo, S Castanys, F Gamarro.   

Abstract

Leishmaniasis is the most important emerging and uncontrolled infectious disease and the second cause of death among parasitic diseases, after Malaria. One of the main problems concerning the control of infectious diseases is the increased resistance to usual drugs. Overexpression of P-glycoprotein (Pgp)-like transporters represents a very efficient mechanism to reduce the intracellular accumulation of drugs in cancer cells and parasitic protozoans, thus conferring a multidrug resistance (MDR) phenotype. Pgps are active pumps belonging to the ATP-binding cassette (ABC) superfamily of proteins. The inhibition of the activity of these proteins represents an interesting way to control drug resistance both in cancer and in infectious diseases. Most conventional mammalian Pgp-MDR modulators are ineffective in the modulation of Pgp activity in the protozoan parasite Leishmania. Consequently, there is a necessity to find effective modulators of Pgp-MDR for protozoan parasites. In this review we describe a rational strategy developed to find specific Pgp-MDR modulators in Leishmania, using natural and semisynthetic dihydro-beta-agarofuran sesquiterpenes from Celastraceae plants. A series of these compounds have been tested on a MDR Leishmania tropica line overexpressing a Pgp transporter to determine their ability to revert the resistance phenotype and to modulate intracellular drug accumulation. Almost all of these natural compounds showed potent reversal activity with different degrees of selectivity and a significant low toxicity. The three-dimensional quantitative structure-activity relationship using the comparative molecular similarity indices analysis (CoMSIA), was employed to characterize the requirements of these sesquiterpenes as modulators at Pgp-like transporter in Leishmania.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16178749     DOI: 10.2174/1381612054864920

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  7 in total

1.  Isolation, biological evaluation and 3D-QSAR studies of insecticidal/narcotic sesquiterpene polyol esters.

Authors:  Shao-peng Wei; Zhi-qin Ji; Hui-xiao Zhang; Ji-wen Zhang; Yong-hua Wang; Wen-jun Wu
Journal:  J Mol Model       Date:  2010-06-08       Impact factor: 1.810

2.  Artemisinin induces doxorubicin resistance in human colon cancer cells via calcium-dependent activation of HIF-1alpha and P-glycoprotein overexpression.

Authors:  C Riganti; S Doublier; D Viarisio; E Miraglia; G Pescarmona; D Ghigo; A Bosia
Journal:  Br J Pharmacol       Date:  2009-03-09       Impact factor: 8.739

Review 3.  The manzamines as an example of the unique structural classes available for the discovery and optimization of infectious disease controls based on marine natural products.

Authors:  Mark T Hamann
Journal:  Curr Pharm Des       Date:  2007       Impact factor: 3.116

4.  Use of antimony in the treatment of leishmaniasis: current status and future directions.

Authors:  Arun Kumar Haldar; Pradip Sen; Syamal Roy
Journal:  Mol Biol Int       Date:  2011-06-08

5.  Semisynthesis and antifeedant activity of new derivatives of a dihydro-β-agarofuran from Parnassia wightiana.

Authors:  Jiang-Jiang Tang; Fei-Yu Zhang; Dong-Mei Wang; Jun-Mian Tian; Shuai Dong; Jin-Ming Gao
Journal:  Int J Mol Sci       Date:  2013-09-26       Impact factor: 5.923

Review 6.  P-glycoprotein inhibitors of natural origin as potential tumor chemo-sensitizers: A review.

Authors:  Hossam M Abdallah; Ahmed M Al-Abd; Riham Salah El-Dine; Ali M El-Halawany
Journal:  J Adv Res       Date:  2014-12-01       Impact factor: 10.479

Review 7.  Drug resistance in visceral leishmaniasis.

Authors:  Helena C Maltezou
Journal:  J Biomed Biotechnol       Date:  2009-11-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.